Johnson Yiu Nam Lau - Jul 20, 2022 Form 4 Insider Report for Athenex, Inc. (ATNXQ)

Role
CEO and Chairman of the Board, Director
Signature
/s/Steven Adams, Attorney-in-Fact
Stock symbol
ATNXQ
Transactions as of
Jul 20, 2022
Transactions value $
$0
Form type
4
Date filed
7/21/2022, 05:32 PM
Previous filing
Jul 18, 2022
Next filing
Aug 1, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ATNXQ Common Stock 3.46M Jul 20, 2022 Direct
holding ATNXQ Common Stock 679K Jul 20, 2022 By Avalon Biomedical (Management) Limited F1, F2
holding ATNXQ Common Stock 165K Jul 20, 2022 By Spouse F2
holding ATNXQ Common Stock 107K Jul 20, 2022 By Avalon Polytom (HK) Limited F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATNXQ Stock Option (Right to Buy) Award $0 +250K $0.00 250K Jul 20, 2022 Common Stock 250K $0.67 Direct F9
holding ATNXQ Stock Option (Right to Buy) 1.2M Jul 20, 2022 Common Stock 1.2M $4.55 Direct
holding ATNXQ Stock Option (Right to Buy) 1.4M Jul 20, 2022 Common Stock 1.4M $7.50 Direct
holding ATNXQ Stock Option (Right to Buy) 1 Jul 20, 2022 Common Stock 1 $11.00 Direct
holding ATNXQ Stock Option (Right to Buy) 54.9K Jul 20, 2022 Common Stock 54.9K $9.00 By Avalon Biomedical (Management) Limited F1, F2
holding ATNXQ Stock Option (Right to Buy) 250K Jul 20, 2022 Common Stock 250K $17.30 Direct
holding ATNXQ Stock Option (Right to Buy) 250K Jul 20, 2022 Common Stock 250K $13.17 Direct F4
holding ATNXQ Stock Option (Right to Buy) 55K Jul 20, 2022 Common Stock 55K $7.32 Direct
holding ATNXQ Stock Option (Right to Buy) 300K Jul 20, 2022 Common Stock 300K $12.45 Direct F5
holding ATNXQ Stock Option (Right to Buy) 150K Jul 20, 2022 Common Stock 150K $3.80 Direct F6
holding ATNXQ Restricted Stock Units 150K Jul 20, 2022 Common Stock 150K Direct F7, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Avalon Biomedical (Management) Limited ("Avalon Biomedical") is an indirect wholly-owned subsidiary of Avalon Global Holdings Limited ("Avalon Global"). Dr. Johnson Lau ("Dr. Lau") owns all of the outstanding interests in Creative Decade Global Limited, which owns 34.63% of the outstanding interests in Avalon Global, and Dr. Lau serves on the board of directors of Avalon Global and has shared voting and dispositive power with respect to the shares held by Avalon Biomedical.
F2 Dr. Lau disclaims beneficial ownership of the reported securities except to the extent, if any, of its or his pecuniary interest therein, and this report shall not be deemed an admission that Dr. Lau is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F3 These shares were acquired pursuant to the terms of a License Agreement dated as of June 29, 2018 by and between Athenex Therapeutics Limited, a wholly-owned subsidiary of Athenex, Inc. ("Athenex") and Avalon Polytom (HK) Limited, a majority-owned affiliate of Avalon Global. The number of shares was determined by dividing $2.0 million by the closing price of Athenex common stock on June 29, 2018.
F4 This option vests in four equal annual installments beginning on February 28, 2020.
F5 This option vests in four equal annual installments beginning on June 5, 2021.
F6 This option vests in four equal annual installments beginning on August 3, 2022.
F7 Each restricted stock unit represents a contingent right to receive one share of stock.
F8 The restricted stock units vest in four equal annual installments beginning on August 3, 2022.
F9 This option vests in four equal annual installments beginning on July 20, 2023.